Truong, Duy Hieu; Tran, Thi Thu Phuong; Nguyen, Hanh Thuy; Phung, Cao Dai; Pham, Tung Thanh; Yong, Chul Soon; Kim, Jong Oh; Tran, Tuan Hiep
Journal of drug targeting
2018Jun ; 8 ( 1 ) :1-19.
PMID : 29741964
ÀúÀÚ »ó¼¼Á¤º¸
Truong, Duy Hieu -
Tran, Thi Thu Phuong -
Nguyen, Hanh Thuy -
Phung, Cao Dai -
Pham, Tung Thanh -
Yong, Chul Soon -
Kim, Jong Oh -
Tran, Tuan Hiep -
ABSTRACT
Immunotherapy holds tremendous promise for improving cancer treatment in which an appropriate stimulator may naturally trigger the immune system to control cancer. Up-to-date, adoptive T-cell therapy has received two new FDA approvals that provide great hope for some cancer patient groups. Nevertheless, expense and safety-related issues require further study to obtain insight into targets for efficient immunotherapy. The development of material science was largely responsible for providing a promising horizon to strengthen immunoengineering. In this review, we focus on T-cell characteristics in the context of the immune system against cancer and discuss several approaches of exploiting engineered particles to manipulate the responses of T cells and the tumour microenvironment.
keyword
Adoptive T-cell therapy; cancer; immunotherapy; particulate systems; tumour microenvironment
¸µÅ©